Press Releases Ceapro Inc.

Equities

CZO

CA1499071076

Delayed Toronto S.E. Other stock markets 11:38:56 2024-05-21 am EDT			5-day change	1st Jan Change
0.27 ^CAD	0.00%		0.00%	+42.11%

May. 17	Aeterna Zentaris Finalizes Some Details for Ceapro Merger	MT
May. 17	Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	Apr. 29	GL
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	Apr. 29	AQ
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris	Mar. 28	GL
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	Mar. 12	GL
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	Mar. 12	AQ
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	Feb. 26	AQ
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company	Feb. 26	GL
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	Feb. 23	GL
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris	Feb. 15	GL
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro	Feb. 15	AQ
Canadian Investment Regulatory Organization Trade Resumption - CZO	Dec. 14	AQ
Canadian Investment Regulatory Organization Trading Halt - CZO	Dec. 14	AQ
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company	Dec. 14	AQ
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	Dec. 13	GL
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	Dec. 13	AQ
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights	Nov. 29	GL
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	Nov. 27	GL
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology	Nov. 07	GL
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update	23-08-29	GL
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update	23-08-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ceapro Inc.

Equities

CZO

CA1499071076

Press Releases

Filters